Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in primary hypercholesterolemia (ODYSSEY CHOICE I)
NCT01926782Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2013
- Primary completion
- Sep 2014
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Started Sep 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01926782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926782.